Author

Amy E. James

Frederick National Laboratory for Cancer ResearchORCID 0000-0002-7669-9220Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Amy L. FunkiD· 1 shared Amy L. Ries· 1 shared Anna A. MarusiakiD· 1 shared Baktiar O. KarimiD· 1 shared Carolyn C. WoodroofeiD· 1 shared Christina M. RobinsoniD· 1 shared Eleanor W. TrotteriD· 1 shared Eric LindbergiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amy L. FunkORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth

Amy L. Funk, Meghri Katerji, Marwa M. Afifi, Katherine M. Nyswaner, Carolyn C. Woodroofe, Zoe C. Edwards, Eric Lindberg, Knickole L. Bergman, Nancy R. Gough, Maxine R. Rubin, Kamila Karpińska, Eleanor W. Trotter, Sweta Dash, Amy L. Ries, Amy E. James, , John Brognard

This study identifies LZK as a therapeutic target in HNSCC by showing its regulation of c-MYC and GOF p53, and demonstrates PROTAC-mediated degradation as a potential treatment.

Science Signaling · Feb 11, 2025Peer-reviewedCancer Biology